Indaptus Therapeutics (INDP) Return on Capital Employed (2021 - 2026)
Indaptus Therapeutics (INDP) posted quarterly Return on Capital Employed of 361.98% for Q1 2026, up 6304.0% year-over-year from 5.65% in Q1 2025, and up 65.02% quarter-over-quarter from 1034.86% in Q4 2025.
Indaptus Therapeutics (INDP) Return on Capital Employed (2021 - 2026) Analysis & Trends
Indaptus Therapeutics' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 361.98% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 6304.0% year-over-year to 361.98%; the TTM figure through Mar 2026 stood at 361.98% (up 6304.0% YoY), while the FY2025 annual figure was 915.72%, down 71713.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 361.98%, up from 1034.86% in the prior quarter.
- The five-year high for Return on Capital Employed was 684.62% in Q2 2025, with the low at 1034.86% in Q4 2025.
- The 5-year median for Return on Capital Employed is 120.56% (2023), against an average of 175.66%.
- Peak annual rise in Return on Capital Employed reached 90126 bps in 2025, while the deepest fall reached 68528 bps in 2025.
- Indaptus Therapeutics' Return on Capital Employed stood at 57.74% in 2022, then plunged by 109 bps to 120.56% in 2023, then tumbled by 190 bps to 349.59% in 2024, then slumped by 196 bps to 1034.86% in 2025, then soared by 65 bps to 361.98% in 2026.
- Business Quant data shows INDP's Return on Capital Employed at 361.98% in Q1 2026, 1034.86% in Q4 2025, and 344.15% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Indaptus Therapeutics | 146.91 Mn | 135.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -361.98% |
| Dec 31, 2025 | -1,034.86% |
| Sep 30, 2025 | -344.15% |
| Jun 30, 2025 | 684.62% |
| Mar 31, 2025 | -425.03% |
| Dec 31, 2024 | -349.59% |
| Sep 30, 2024 | -258.46% |
| Jun 30, 2024 | -216.64% |
| Mar 31, 2024 | -139.19% |
| Dec 31, 2023 | -120.56% |
| Sep 30, 2023 | -96.06% |
| Jun 30, 2023 | -78.37% |
| Mar 31, 2023 | -67.13% |
| Dec 31, 2022 | -57.74% |
| Sep 30, 2022 | -47.80% |
| Jun 30, 2022 | -43.37% |
| Mar 31, 2022 | -29.92% |
| Dec 31, 2021 | -20.55% |
| Sep 30, 2021 | -20.15% |
| Jun 30, 2021 | -25.96% |